Literature DB >> 20697853

An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection.

Masao Hagihara1, Jian Hua, Morihiro Inoue, Naohiko Michikawa.   

Abstract

A 69-year-old man suffered from a fractured cervical vertebra, and magnetic resonance imaging revealed a solitary mass occupying the injured lesion. Surgical resection of the mass was conducted, and the infiltration of plasma cells expressing IgE-lambda monoclonal protein was shown on pathological investigation. Concurrently, a monoclonal band of IgE-lambda was shown in the sera on immunoelectrophoresis, and the proliferation of plasma cells (more than 10%) was also detected in bone marrow aspirates. A rare IgE-multiple myeloma (MM) was diagnosed, and careful monthly follow-up was started. During this observation period, the level of IgE gradually increased and, at 2 years after the initial diagnosis, bilateral leg edema and ascites with marked hepatosplenomegaly appeared. Combination chemotherapy of melphalan and prednisolone (MP) was started, which resulted in the partial, transient resolution of symptoms. Additional treatment with bortezomib and dexamethasone could neither resolve these clinical symptoms nor decrease the serum IgE concentration. At 5 months after the start of chemotherapy, amyloid deposition was suggested based on typical echocardiographic findings, and the diagnosis of amyloidosis was confirmed based on the histopathology of a liver biopsy. In spite of MP plus thalidomide treatment, cardiac failure due to amyloidosis aggravated, and the patient died of multiple organ failure. This is the second reported case in which IgE-MM was complicated by systemic amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697853     DOI: 10.1007/s12185-010-0658-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Martha Q Lacy; Jerry A Katzmann; S Vincent Rajkumar; Roshini S Abraham; Suzanne R Hayman; Shaji K Kumar; Raynell Clark; Robert A Kyle; Mark R Litzow; David J Inwards; Stephen M Ansell; Ivana M Micallef; Luis F Porrata; Michelle A Elliott; Patrick B Johnston; Philip R Greipp; Thomas E Witzig; Steven R Zeldenrust; Stephen J Russell; Dennis Gastineau; Morie A Gertz
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

Review 2.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

Review 3.  IgE myeloma: a case presentation and a review of the literature.

Authors:  K J Kairemo; M Lindberg; M Prytz
Journal:  Scand J Clin Lab Invest       Date:  1999-10       Impact factor: 1.713

Review 4.  IgE lambda monoclonal gammopathy and amyloidosis.

Authors:  J M Jako; T Gesztesi; I Kaszas
Journal:  Int Arch Allergy Immunol       Date:  1997-04       Impact factor: 2.749

5.  A new case of IgE myeloma.

Authors:  F Invernizzi; G Monti; A G Caviglia; P Meroni; C Zanussi
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

6.  IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha.

Authors:  N Yamagata; C Shimazaki; H Goto; T Hirata; E Ashihara; N Oku; T Inaba; N Fujita; M Nakagawa
Journal:  Am J Hematol       Date:  1994-03       Impact factor: 10.047

Review 7.  How I treat amyloidosis.

Authors:  Raymond L Comenzo
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

8.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors:  Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

9.  Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

Authors:  Ashutosh D Wechalekar; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Haematologica       Date:  2008-02       Impact factor: 9.941

10.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

View more
  2 in total

1.  Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study.

Authors:  Hiroyuki Sato; Yusuke Komiya; Shigeru Hoshino
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

2.  IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature.

Authors:  Subhashis Mitra; Sanghamitra Mukherjee; Hema Chakraborty; Maitreyee Bhattacharyya
Journal:  Indian J Hematol Blood Transfus       Date:  2014-09-03       Impact factor: 0.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.